menu
    • menu
    [{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AB201","moa":"Tissue factor pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"University Medical Center of Johannes Gutenberg University Mainz","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Recombinant Nematode Anticoagulant Protein c2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ University Medical Center of Johannes Gutenberg University Mainz","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ University Medical Center of Johannes Gutenberg University Mainz"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Nematode Anticoagulant Protein c2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Fairmount","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Fairmount"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ORKA-002","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Oruka Therapeutics

    Menu

    Oruka Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-002

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oruka Therapeutics Announces Preclinical Data for ORKA-002

                            Details : ORKA-002 is a novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-17A/F. It is being evaluated for the treatment of plaque psoriasis.

                            Product Name : ORKA-002

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 07, 2025

                            Lead Product(s) : ORKA-002

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oruka Doses First Participants in Phase 1 Trial of ORKA-001 Anti-IL-23p19 Antibody

                            Details : ORKA-001 is a IL-23p19 inhibitor, antibody. It is currently being evaluated in early-stage clinical trials for the treatment of psoriasis.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 19, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Braidwell LP

                            Deal Size : $200.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Oruka Therapeutics Announces $200 Million Private Placement

                            Details : The net proceeds from the financing will be used to support the clinical development of ORKA-001, currently being evaluated in early-stage clinical trials for the treatment of psoriasis.

                            Product Name : ORKA-001

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 12, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Braidwell LP

                            Deal Size : $200.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Oruka Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            ARCA Biopharma Completes Merger with Oruka Therapeutics, Implements Stock Split

                            Details : Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                            Product Name : ORKA-001

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 29, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Oruka Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Oruka Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

                            Details : Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                            Product Name : ORKA-001

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 03, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Oruka Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Fairmount

                            Deal Size : $275.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

                            Details : The net proceeds will be used to advance Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                            Product Name : ORKA-001

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 03, 2024

                            Lead Product(s) : ORKA-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Fairmount

                            Deal Size : $275.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Nematode Anticoagulant Protein c2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ARCA Biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

                            Details : This clinical trial used a 1:1:2 randomization between lower dose rNAPc2, higher dose rNAPc2 and standard of care heparin that was delivered in prophylactic doses in 93% of the patients. rNAPc2 patients received three sub-cutaneous (SC) doses.

                            Product Name : rNAPc2

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : Recombinant Nematode Anticoagulant Protein c2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bucindolol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

                            Details : In a GENETIC-AF Phase 2b clinical trial, the prevalence of bradycardia was significantly lower for Gencaro compared to metoprolol. Gencaro, is an investigational, pharmacologically unique beta-blocker for the treatment of atrial fibrillation in heart fai...

                            Product Name : Gencaro

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2022

                            Lead Product(s) : Bucindolol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completio...

                            Details : rNAPc2 (AB201) is a small recombinant protein being developed as a potential treatment for COVID-19 and potentially other viral diseases and a potent, selective inhibitor of tissue factor (TF).

                            Product Name : AB201

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2021

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed

                            Oruka Therapeutics

                            U.S.A arrow
                            NextGen Biomed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completio...

                            Details : Recombinant nematode anticoagulant protein c2 (rNAPc2) is a novel and potent inhibitor of fVIIa/TF that may improve current therapeutic strategies used in COVID-19.

                            Product Name : AB201

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2021

                            Lead Product(s) : rNAPc2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth